Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis
Javier Fernández, Paolo Angeli, Jonel Trebicka, Manuela Merli, Thierry Gustot, Carlo Alessandria, Niels Kristian Aagaard, Andrea de Gottardi, Tania M Welzel, Alexander Gerbes, German Soriano, Victor Vargas, Agustin Albillos, Francesco Salerno, Francois Durand, Rafael Bañares, Rudolf Stauber, Verónica Prado, Mireya Arteaga, María Hernández-Tejero, Fátima Aziz, Filippo Morando, Christian Jansen, Barbara Lattanzi, Christophe Moreno, Daniela Campion, Henning Gronbaek, Rita Garcia, Cristina Sánchez, Elisabet García, Alex Amorós, Marco Pavesi, Joan Clària, Richard Moreau, Vicente Arroyo, Javier Fernández, Paolo Angeli, Jonel Trebicka, Manuela Merli, Thierry Gustot, Carlo Alessandria, Niels Kristian Aagaard, Andrea de Gottardi, Tania M Welzel, Alexander Gerbes, German Soriano, Victor Vargas, Agustin Albillos, Francesco Salerno, Francois Durand, Rafael Bañares, Rudolf Stauber, Verónica Prado, Mireya Arteaga, María Hernández-Tejero, Fátima Aziz, Filippo Morando, Christian Jansen, Barbara Lattanzi, Christophe Moreno, Daniela Campion, Henning Gronbaek, Rita Garcia, Cristina Sánchez, Elisabet García, Alex Amorós, Marco Pavesi, Joan Clària, Richard Moreau, Vicente Arroyo
Abstract
Background & aims: We performed a randomized trial to determine whether albumin should be administered to patients with infections unrelated to spontaneous bacterial peritonitis (SBP).
Methods: We performed a multicenter, open-label trial in which 118 patients with cirrhosis, non-SBP infections, and additional risk factors for poor outcome were randomly assigned to receive antibiotics plus albumin (study group; n = 61) or antibiotics alone (control group; n = 57). The primary outcome was in-hospital mortality; secondary outcomes were effect of albumin on disease course.
Results: There were no significant differences at baseline between groups in results from standard laboratory tests, serum markers of inflammation, circulatory dysfunction, or liver severity scores. However, the combined prevalence of acute on chronic liver failure (ACLF) and kidney dysfunction was significantly higher in the study group (44.3% vs 24.6% in the control group; P = .02), indicating greater baseline overall severity. There was no significant difference in the primary outcome between groups (13.1% in the study group vs 10.5% in the control group; P = .66). Circulatory and renal functions improved in only the study group. A significantly higher proportion of patients in the study group had resolution of ACLF (82.3% vs 33.3% in the control group; P = .03). A significantly lower proportion of patients in the study group developed nosocomial infections (6.6% vs 24.6% in the control group; P = .007).
Conclusions: In a randomized trial of patients with advanced cirrhosis and non-SBP infections, in-hospital mortality was similar between those who received albumin plus antibiotics vs those who received only antibiotics (controls). However, patients given albumin were sicker at baseline and, during the follow-up period, a higher proportion had ACLF resolution and a lower proportion had nosocomial infections. ClinicalTrials.gov no: NCT02034279.
Keywords: Acute-on-Chronic Liver Failure; Immune-Modulation; Mortality; Nosocomial Infections.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.
Source: PubMed